ARTICLE | Company News
Eli Lilly, Mitsubishi-Tokyo Pharmaceuticals Inc., Sankyo deal
January 2, 2001 8:00 AM UTC
Mitsubishi-Tokyo granted LLY exclusive rights outside Japan to develop and market MCC-478, an antiviral nucleotide analog in Phase I testing to treat hepatitis B virus (HBV) infection. ...